Anixa Biosciences, Inc.
ANIX
$3.38
-$0.17-4.79%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | -100.00% | -100.00% |
| Gross Profit | -- | -- | -- | -100.00% | -100.00% |
| SG&A Expenses | -5.55% | -0.76% | 18.18% | 5.97% | 14.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.33% | 10.87% | 23.26% | 16.47% | 10.56% |
| Operating Income | -1.33% | -12.80% | -25.61% | -18.58% | -12.58% |
| Income Before Tax | -4.39% | -16.15% | -27.88% | -16.46% | -7.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.39% | -16.15% | -27.88% | -16.46% | -7.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -16.67% | 13.11% | 21.01% | 2.84% | 8.27% |
| Net Income | -4.65% | -16.19% | -27.96% | -16.65% | -7.04% |
| EBIT | -1.33% | -12.80% | -25.61% | -18.58% | -12.58% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.11% | -12.75% | -24.31% | -13.81% | -4.88% |
| Normalized Basic EPS | -2.31% | -12.79% | -24.44% | -14.01% | -4.90% |
| EPS Diluted | -2.11% | -13.21% | -24.31% | -14.28% | -5.34% |
| Normalized Diluted EPS | -2.31% | -12.79% | -24.44% | -14.01% | -4.90% |
| Average Basic Shares Outstanding | 2.55% | 3.13% | 2.96% | 2.36% | 1.92% |
| Average Diluted Shares Outstanding | 2.55% | 3.13% | 2.96% | 2.36% | 1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |